Who is sponsoring NCT06939452?

NCT06939452 is sponsored by Yongxu Jia.

What drugs are being tested in NCT06939452?

Interventions in NCT06939452: anlotinib +TQB2450 + Oxaliplatin+S-1.

Is NCT06939452 still recruiting?

NCT06939452 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT06939452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Active, enrolled Phase 2 Last updated 7 April 2026

What this trial tests

Phase 2 trial testing anlotinib +TQB2450 + Oxaliplatin+S-1 in Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma in 37 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 June 2023

Primary endpoint
1 June 2026

1 June 2026

Quick facts

Lead sponsor	Yongxu Jia
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	7 June 2023
Primary completion	1 June 2026
Estimated completion	1 June 2026
Sites	1 location across China

Drugs / interventions tested

anlotinib +TQB2450 + Oxaliplatin+S-1 — full drug profile →

Conditions studied

Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma — all drugs for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma →

Sponsor

Yongxu Jia — full company profile →

Who can join

18 and older, any sex, with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era.
Cheng P, Gu H, Chen Q, Zhao G, et al · · 2026 · PMID 42052493 · DOI 10.3389/fonc.2026.1748214

Verify or expand the search:

Other Yongxu Jia trials

Trials by the same sponsor.

NCT06814548 — Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Re · not yet recruiting
NCT06923020 — Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Can · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06939452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yongxu Jia
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06939452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing